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Free and total 1,25.dihydroxyvitamin D levels in subjects with renal
disease. Patients with nephrotic syndrome and varying degrees of renal
failure, including those on chronic hemo- and peritoneal dialysis, may
have low serum concentrations of total I ,25-dihydroxyvitamin D
[l,25(OH)2D]. However, it is unknown whether the true activity of
1 ,25(OH)2D is better reflected by the free I ,25(OH)2D fraction. We
measured total 1 ,25(OH)2D, free 1 ,25(OH)2D, and vitamin-D-binding
protein (DBP) in normal subjects (group A), subjects with moderate
renal failure (group B), subjects on hemodialysis (group C), subjects on
peritoneal dialysis (group D), and subjects with nephrotic syndrome(group E). The serum concentrations of total and free 1 ,25(OH)2D
decreased with worsening renal function in groups A through C, with a
high degree of correlation (r = 0.974, P < 0.0001). Levels of DBP and
the percent free I ,25(OH)2D remained constant in these groups. Pa-
tients on peritoneal dialysis and nephrotic patients had lower levels of
DBP (203 14 gIml and 371 46 gIml, respectively) than normal
subjects (436 33 g/ml) and had significantly higher percent free
l,25(OH)2D (0.98 0.13% and 1.27 0.14%, respectively) compared
to 0.63 0.03% (P < 0.05). Thus, the loss of DBP in these patients
correlated with a rise in the percent free 1 ,25(OH)2D. We conclude that
levels of total I ,25(OH)2D are an accurate representation of 1 ,25(OH)2D
status in normal subjects, subjects with renal insufficiency without
nephrotic syndrome, and hemodialysis patients. In peritoneal dialysis
and nephrotic patients, who lose DBP, measurements of free
1 ,25(OH)2D may be necessary in order to accurately assess 1 ,25(OH)2D
status.
Patients with end-stage renal disease (ESRD) have low levels
of total 1 ,25-dihydroxyvitamin D [1 ,25(OH)2D] as a result of
decreased activity of 1-alpha hydroxylase in the proximal
convoluted tubules. In addition, patients who have ESRD and
are treated with peritoneal dialysis can lose substantial amounts
of vitamin-D-binding protein (DBP) through the peritoneal
membrane [1]. Similarly, patients with nephrotic syndrome may
lose DBP into the urine because of glomerular capillary wall
abnormalities [2, 3]. Since both 25-dihydroxyvitamin D
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[25(OH)D] and 1 ,25(OH)2D are highly protein bound (>99%) in
the blood, primarily to DBP, loss of DBP into the peritoneal
fluid or urine could therefore result in decreased concentrations
of one or more vitamin D metabolites in the serum [2—12].
However, as is the case with the thyroid hormones, cortisol,
and testosterone, the circulating unbound fraction (that is, free
vitamin D) may be physiologically active. In fact, documented
changes in serum concentrations of free 1 ,25(OH)2D have been
found to correspond to various physiologic and pathologic
states such as pregnancy and liver disease [13, 14]. Few data are
available on levels of free vitamin D in conditions associated
with decreased concentrations of vitamin D in the serum (such
as in renal failure, nephrotic syndrome, and peritoneal dialysis).
The purpose of our investigation was to assess whether levels of
total 1 ,25(OH)2D accurately reflect 1 ,25(OH)2D status in these
states, or whether levels of free 1,25(OH)2D must also be
measured. Additionally, because of the relationship between
DBP and 25(OH)D, and because the production of 24,25-
dihydroxyvitamin D [24,25(OH)2D] is influenced by serum
concentrations of both 25(OH)D and 1 ,25(OH)2D [15], we
measured levels of these vitamins as well.
Methods
Blood was sampled from four groups of age-, race-, and
sex-matched persons: normal volunteers (group A, N = 10);
non-nephrotic subjects with moderate to severe renal failure,
glomerular filtration (GFR) 12 to 60 mllmin (group B, N = 9);
patients with end-stage renal disease (ESRD) on chronic hemo-
dialysis (group C, N = 10); and patients with ESRD on
continuous ambulatory peritoneal dialysis (group D, N = 10).
Hemodialysis patients were dialyzed for three to four hours,
three times a week, using hollow-fiber cellulose-acetate mem-
branes at blood flows of 200 to 300 mllmin against a bath
containing sodium, 140 mEq/liter; calcium, 3.5 mEq/liter; and
potassium adjusted for serum potassium levels. Five patients
were dialyzed with bicarbonate (30 mEqlliter) bath and five
others with acetate. Patients receiving continuous ambulatory
peritoneal dialysis (CAPD) underwent four 2.0-liter exchanges
daily using standard peritoneal dialysate (DIANEAL, Baxter
Laboratories, Deerfield, Illinois, USA) containing calcium, 3.5
mEq/liter. The dextrose concentration was varied according to
patients' weight requirements. Serum albumin concentrations
in this group of patients ranged from 30 to 38 glliter (mean 34
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Table 1. Levels of total I ,25-dihydroxyvitamin D [1 ,25(OH)2D}, vitamin D-binding protein (DBP) and free fraction of I ,25(OH)2D in subjects
who were normal (N), had moderate renal failure (MRF), were on hemodialysis (HD), were on peritoneal dialysis (PD) or had nephrotic
syndrome (NS)
Subjects I ,25(OH)2D
Total DBP Percent AbsoluteGroup Gender Ageb
(status) N M/F yr pg/mi jig/mi free free fg/mi
A (N) 10 5/5 65 28 4 436 33 0.63 0.03 172 26
B (MRF) 9 5/4 66 14 2C 483 34 0.58 0,04 85 13C
C (HD) 10 5/5 64 2c,d 453 33 0.62 0.03 30 14c
D (PD) 10 5/5 64 2 203 14c,d,e 0.98 013c 19 9C
E (NS) 9 6/3 49 16 3c.e.f 371 46d,f 1.27 014C,d.e.f 202 53'
Abbreviations are: N, number in group; M, male; F, female.
a Only seven subjects in group D for total 1 ,25(OH)2Db Mean age in years
P < 0.05 compared to subjects who were normald P < 0.05 compared to subjects who had MRF
p < 0.05 compared to subjects who were on HD
P < 0.05 compared to subjects who were on PD
glliter). No hemodialysis patient had an albumin level less than
33 g/liter. Urine output in all ESRD patients was insignificant.
Blood was also obtained from nine subjects with nephrotic
syndrome (group E). Four had normal renal function (GFR > 80
mi/mm) and five had a GFR <60 ml/min (range 9 to 55 mllmin,
mean GFR = 37 ml/min). In those with normal GFR, nephrosis
was secondary to membranous nephropathy (2), minimal
change disease (1), and idiopathic mesangial proliferation (1),
while in patients with renal insufficiency the causes of nephrotic
syndrome were diabetes (2), amyloidosis (1), membranoprolif-
erative glomerulonephritis type I (1), and focal segmental
glomerulosclerosis (1). The mean concentration of serum albu-
min in this group was 30 g/liter (range 16 to 44 g/liter). The mean
rate of urinary protein excretion was 6.8 g/day (range 3,5 to 13.2
g/day).
None of the participants was pregnant or taking estrogens,
anti-convulsants, or vitamin D supplements. Patients with liver
disease, overt malnutrition, malabsorption, or significant acido-
sis (serum bicarbonate level less than 18 mmol/liter) were also
excluded. Phosphate binders were continued in patients requir-
ing them.
Total 1,25(OH)2D was measured by radioreceptor assay
following HPLC purification as previously described [16], ex-
cept that the volume of serum analyzed was 5 ml to permit
greater detection capability for patients with extremely low
levels of 1 ,25(OH)2D. The intra- and interassay variations for
total 1 ,25(OH)2D were 8% and 13%, respectively. The limit of
detection using radioactive l,25(OH)2D at a specific activity of
120 Ci/mmol was 3 pg/mI using the 5-ml serum sample, with
65% recovery during purification. The 25(OH)D and
24,25(OH)2D fractions were assayed separately using the rat
serum binding protein system [151. Percent free 1,25(OH)2D
was determined by the method of Bikle et al [14]. The concen-
tration of free 1 ,25(OH)2D was calculated by multiplying the
total level of 1 ,25(OH)2D by the percent free. DBP was quan-
tified using the rocket immunoelectrophoresis assay [17]. Intra-
assay coefficient of variation for the percent free I ,25(OH)2D
was 6.6%, while interassay coefficient of variation was 14.2%.
Group data are expressed as the mean SEM. Analysis of
variance was used to determine the significance of the differ-
ences between groups [18], except for 24,25(OH)2D, for which
Kruskal-Wallis one-way analysis of variance was employed
[191. Correlations between sets of data used linear regression
[18].
Results
The mean serum concentrations of total 1 ,25(OH)2D, DBP,
absolute level of free 1 ,25(OH)2D, and percent free 1 ,25(OH)2D
for the five groups are shown in Table 1. Total 1 ,25(OH)2D
concentrations decreased as renal function worsened, with
progression from normal subjects (28 4 pg/mI) to subjects
with moderate renal failure (14 2 pg/ml) to hemodialysis
patients (5 2 pg/mI). There was a statistically significant
difference (P < 0.05) between each of these groups. Patients on
CAPD had the lowest mean concentration (2 1 pg/mi). Four
patients demonstrated undetectable values (<3 pg/ml). How-
ever, the mean value was not statistically different from that of
hemodialysis patients (P > 0.05). The mean level of total
1 ,25(OH)2D in nephrotic subjects (16 3 pg/mI) was interme-
diate between normal and hemodialysis/CAPD patients (P <
0.05).
The mean DBP concentration remained constant as renal
function deteriorated from normal (436 33 jig/mI) to moderate
renal failure (483 34 jig/mI) to hemodialysis patients (453 33
jig/mI). There were no significant differences (P > 0.05) be-
tween these groups. However, the mean DBP concentration
was significantly lower in peritoneal dialysis patients (203 14
jig/mI; P < 0.05). Nephrotic subjects had a mean DBP concen-
tration (371 46 jig/mI) intermediate between CAPD patients
(P <0.05) and normal subjects, although statistical significance
at the P < 0.05 level was not achieved with the latter group.
The mean percent free 1,25(OH)2D also remained constant,
with progression from normal renal function (0.63 0.03%) to
moderate renal failure (0.58 0.04%) to hemodialysis (0.62
0.03%), with no significant differences between these groups.
The CAPD and nephrotic patients possessed significantly
higher levels of percent free 1 ,25(OH)2D (0.98 0.13% and 1.27
0.14%, respectively) than all other groups (P < 0.05), and the
difference between the two was also statistically significant.
The absolute concentration of free 1 ,25(OH)2D Lthe product
of total and percent free 1 ,25(OH)2D] declined from normal
subjects (172 26 fg/ml) to subjects with moderate renal failure
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Fig. 1. Correlation between total 1,25(OH)2D and free 1,25(OH)2D
serum levels in normal subjects (•), subjects with moderate renal
failure (•) and subjects with ESRD on chronic hemodialysis (A) (r =
0.974, P < 0.0001). There was no correlation using the same variables
in peritoneal dialysis and nephrotic patients.
(85 13 fg/ml) to hemodialysis patients (30 14 fglml).
Although CAPD patients had elevated levels of percent free
1 ,25(OH)D, their absolute levels of free 1 ,25(OH)2D remained
low (19 9 fglml). Nephrotic subjects had an absolute concen-
tration of free I ,25(OH)2D (202 + 53 fg/ml) that was not
significantly different from that of normal subjects.
There was a linear correlation between total levels of serum
I ,25(OH)2D and the absolute levels of free 1 ,25(OH),D when
data from normal subjects, those with moderate renal failure,
and those on chronic hemodialysis were pooled (r = 0.974; P <
0.00001) (Fig. 1). There was no such correlation when data from
CAPD and nephrotic patients were added or when the data
were analyzed separately.
The mean serum concentrations of 25(OH)D and
24,25(OH)2D in each group of subjects are compared in Table 2.
There was no statistical difference in 25(OH)D levels in normal
subjects (19 2 ng/ml), subjects with moderate renal failure (20
2 ng/ml), and subjects on hemodialysis (15 3 nglml). CAPD
patients had a significantly lower mean 25(OH)D concentration
(8 2 ng/ml), and nephrotic patients had an intermediate level
(12 3 nglml).
The mean serum concentrations of 24,25(OH)2D were lower
in subjects with moderate renal failure (1.3 1.0 nglml) and in
those on hemodialysis (1.0 0.5 ng/ml) than in normal subjects
(3.6 0.6 nglml). Both hemodialysis patients and nephrotic
syndrome patients had mean values of 24,25(OH)2D signifi-
cantly less than those of normal subjects (P < 0.05). The level
of 24,25(OH)2D was undetectable in all CAPD patients studied
(<0.3 nglml) and was significantly decreased compared to that
of normal subjects (P < 0.05).
Subjects with nephrotic syndrome were then stratified ac-
cording to renal function: GFR > 80 mI/mm versus GFR < 55
mllmin, as depicted in Table 3. The mean daily protein excre-
tion and the mean serum albumin concentration in subjects with
Table 2. Levels of total 25-dihydroxyvitamin D [25(OH)D] and 24,25-
dihydroxyvitamin D [24,25(OH)2D} in subjects who were normal (N),
had moderate renal failure (MRF), were on hemodialysis (HD), were
on peritoneal dialysis (PD) or had nephrotic syndrome (NS)
Group Status N
Total
25(OH)D
Total
24,25(OH)2D
ag/mi
A N 10 19±2 3.6±0.6
B MRF 9 20 2 1.3 1.0
C HD 10 15 3 1.0 0.5
D PD 7 8 2a.t,,, Nondetectablea
E NS 10 12 3b o.2a
Kruskal-Wallis one-way analysis of variance used to compare
groups. Abbreviation is: N, number in group.
a P < 0.05 compared to subjects who were normalbP < 0.05 compared to subjects who had MRF
c P < 0.05 compared to subjects who were on HD
d P < 0.05 compared to subjects who were on PD
Table 3. Normal versus decreased glomerular filtration rate in
subjects with nephrotic syndrome
Glomerular filtration rate
Normal
(N=4)
Decreased
(N=5)
Total l,25(OH)2D pg/mi
Vitamin D-binding protein sg/ml
Free fraction of I ,25(OH),D fglml
Percent free l,25(OH)2Da
Total 25(OH)D iig/inl
Total 24,25(OH)2D ng/mr
15 5
373 57
241 97
1.45 0.10
12 5
0.9 0.4
16 5
370 75
170 62
1.12 0.23
11 3
0.1 0.1
a P < 0.05 between groups
a normal GFR were 79 and 25 gIl, respectively, while these
same parameters were 59 and 33 g/l, respectively, in nephrotic
subjects with a decreased GFR. There were no differences in
the mean concentrations of total 1,25(OH)2D, total 25(OH)D, or
DBP between these groups. Nephrotic patients with renal
dysfunction had a lower mean 24,25(OH)2D level (0.1 0.1
ng/ml) than those with normal renal function (0.9 0.4 ng/ml; P
<0.05). The level of percent free 1 ,25(OH)2D was significantly
higher in nephrotic patients with normal GFR than in those with
decreased GFR (1.45 0.10% vs. 1.12 0.23%, respectively;
P < 0.05).
Discussion
To our knowledge, no one has measured free 1 ,25(OH)2D in
subjects with renal failure. Employing the centrifugal ultrafil-
tration method of Bikle et al [141, we directly measured the level
of percent free and total concentration 1 ,25(OH)2D in subjects
with varying degrees of renal dysfunction (including patients on
chronic hemodialysis and peritoneal dialysis) and those with
nephrotic syndrome. DBP, total 25(OH)D, and total
24,25(OH)2D were also assayed. In subjects with moderate
renal failure (group B, GFR = 20 to 60 mI/mm) without
nephrotic syndrome and those on chronic hemodialysis (group
C), the serum concentration of total 1 ,25(OH)2D correlated well
with the concentration of free 1 ,25(OH)2D. Thus, measuring
free l,25(OH)2D to assess l,25(OH),D status is unnecessary in
these patients. As anticipated, the serum concentrations of
U
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DBP and 25(OH)D in these same patients were normal because
liver disease was a criterion for exclusion.
Nephrotic patients and patients on peritoneal dialysis lose
DBP and its bound vitamin D metabolites into the peritoneal
fluid or urine [1—121. As has been shown by Bikie et al [14] in
patients with severe liver disease, low serum DBP concentra-
tions may lead to a higher level of percent free 1 ,25(OH)2D
resulting in an absolute level of free 1 ,25(OH)2D comparable to
that of normal subjects. Indeed, we found lower levels of total
1 ,25(OH)2D in groups D (CAPD) and E (nephrotic syndrome)
than in normal subjects. Additionally, levels of DBP and
25(OH)D were lower and the level of percent free 1 ,25(OH)2D
was increased in both groups.
A binding inhibitor that could account for increased levels of
percent free in patients with CAPD and nephrotic syndrome
seems unlikely because the level of percent free was not
increased in patients who had moderate renal failure or were on
hemodialysis. However, the rise in level of percent free in
CAPD patients was insufficient to raise the absolute serum
concentration of free 1 ,25(OH)2D to a level comparable to
normal. On the other hand, in nephrotic subjects, the increase
in level of percent free resulted in normal levels of the free
vitamin. This finding contrasts with data reported by Auwerx et
al [4], who found a low free 1 ,25(OH)2D index in 18 nephrotic
subjects who had normal GFR. This index, however, was
calculated from the molar ratio of total I ,25(OH)2D to level of
DBP, which assumes that changes in the level of DBP will result
in predictable changes in total I ,25(OH)2D. Given the excessive
binding sites from DBP compared to available I ,25(OH)2D, this
assumption may be erroneous. (The normal serum concentra-
tion of DBP is 400 g/ml with one binding site per molecule,
compared to a normal 1 ,25(OH)2D serum concentration of 20 to
50 pg/ml.) Furthermore, there was no correlation between
levels of DBP and total 1 ,25(OH)2D in our study. Direct
measurement of the free hormone, therefore, would seem
preferable in patients with nephrotic syndrome or on peritoneal
dialysis.
When nephrotic patients were stratified according to renal
function (GFR> 80 mI/mm vs. GFR < 55 mI/mm), those with
normal renal function had significantly higher levels of percent
free I ,25(OH)2D than those with renal insufficiency. The abso-
lute level of free 1 ,25(OH)2D was higher in those with a normal
GFR but did not achieve statistical significance when compared
to those with decreased GFR. The number of nephrotic patients
studied in each group was small and further studies are needed
to clarify this issue.
Studies that have assessed bone histology in nephrotic pa-
tients with a normal GFR have shown wide variability in the
degree of osteomalacia, from 0% to 100% [5, 8, 9, 20]. This
variability, the lack of controls [5, 9], the absence of vitamin D
levels [20], and the inability to correlate osteomalacia with
levels of vitamin D metabolites [8, 9] have rendered interpreta-
tion of these data difficult. Further controlled studies assessing
bone histology in relation to total and free concentrations of
1 ,25(OH)2D and concentration of 25(OH)D are needed. Our
study indicates that nephrotic patients have adequate levels of
physiologically active (free) 1 ,25(OH)2D.
In patient groups A through C, there was a downward trend
of 24,25(OH)2D levels, with worsening renal function that
reached statistical significance for dialysis patients. Since the
kidney is the major site of the 24-hydroxylase enzyme, lower
levels of 24,25(OH)2D with renal failure are expected. The low
level of this vitamin in nephrotic syndrome patients probably
reflects the low serum total 25(OH)D level and the fact that five
of nine patients had decreased renal function.
In summary, the serum concentrations of total and free
l,25(OH)2D correlate well and progressively decrease as renal
function worsens, excluding patients on peritoneal dialysis or
those with nephrotic syndrome. The serum concentrations of
DBP and 25(OH)D are unaffected by renal function. Therefore,
levels of total 1 ,25(OH)2D accurately reflect 1 ,25(OH)2D status
in patients with varying degrees of renal failure as long as levels
of DBP remain normal. The loss of DBP and its bound vitamin
D metabolites through the peritoneal membrane or an abnormal
glomerular capillary wall results in a rise in the percent free
1 ,25(OH)2D. This may necessitate measuring the serum con-
centrations of both total and free 1 ,25(OH)2D in patients with
nephrotic syndrome or those on peritoneal dialysis when as-
sessing 1,25(OH)2D status.
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